Insider trade

Officer sold ~$4.92M of JAZZ shares in the open market

Traded Aug 27, 2026 · Filed Sep 1, 2026

Why it stands out

Jazz Pharmaceuticals's Global Head of R&D & CMO sold $4.92M of Jazz Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$4,921,596

Shares × reported transaction price

Timing vs results

24 days after results of Aug 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−1.5%	+0.6%	−2.0%
30 days	−4.4%	+0.3%	−4.7%

Past results only. Not a forecast.

This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Scheduled in advance3w ago

4w ago

Routine share withholding; mechanical by default.

Scheduled in advance4w ago